Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. BRIMOCHEK -T EYE DROPS SOLUTION [SIN15191P]

BRIMOCHEK -T EYE DROPS SOLUTION [SIN15191P]

Active ingredients: BRIMOCHEK -T EYE DROPS SOLUTION

Last updated 26 October 2025

On this page

Product Info
CONTRAINDICATIONS

Product Info

BRIMOCHEK -T EYE DROPS SOLUTION

[SIN15191P]

Product information

Active Ingredient and Strength

BRIMONIDINE 1.3 MG/ML EQV BRIMONIDINE TARTRATE - 2 MG/ML
TIMOLOL MALEATE 6.8 MG/ML EQUIVALENT TO TIMOLOL - 5 MG/ML

Dosage Form

SOLUTION, STERILE

Manufacturer and Country

INDOCO REMEDIES LIMITED (PLANT II) - INDIA

Registration Number

SIN15191P

Licence Holder

GOLDPLUS UNIVERSAL PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01ED51

INDICATIONS AND USAGE
Reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers.

DOSAGE AND ADMINISTRATION
Recommended dosage in adults (including the elderly) The recommended dose is one drop of Brimocheck T in the affected eye(s) twice daily, approximately 12 hours apart. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac be compressed at the medial canthus (punctual occlusion) for one minute. This should be performed immediately following the instillation of each drop. To avoid contamination of the eye or drops do not allow the dropper tip to come into contact with any surface.

CONTRAINDICATIONS

  • Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease

  • Sinus bradycardia, sick sinus syndrome, sino-atrial nodal block, second or third degree atrioventricular block, not controlled with a pace-maker, overt cardiac failure, cardiogenic shock

  • Use in neonates and infants (children under the age of 2 years; see PAEDIATRIC USE section – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)

  • Patients receiving monoamine oxidase (MAO) inhibitor therapy

  • Patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin)

  • Hypersensitivity to the active substances or any of the excipients